- Home
- LAES vs MREO Comparison
LAES vs MREO Comparison
Compare LAES & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAES
- MREO
- Stock Information
- Founded
- LAES 2022
- MREO 2015
- Country
- LAES Switzerland
- MREO United Kingdom
- Employees
- LAES N/A
- MREO N/A
- Industry
- LAES Semiconductors
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- LAES Technology
- MREO Health Care
- Exchange
- LAES Nasdaq
- MREO Nasdaq
- Market Cap
- LAES 453.6M
- MREO 438.8M
- IPO Year
- LAES N/A
- MREO N/A
- Fundamental
- Price
- LAES $2.98
- MREO $1.68
- Analyst Decision
- LAES Strong Buy
- MREO Strong Buy
- Analyst Count
- LAES 1
- MREO 5
- Target Price
- LAES $6.00
- MREO $7.20
- AVG Volume (30 Days)
- LAES 10.4M
- MREO 4.4M
- Earning Date
- LAES 09-24-2025
- MREO 08-12-2025
- Dividend Yield
- LAES N/A
- MREO N/A
- EPS Growth
- LAES N/A
- MREO N/A
- EPS
- LAES N/A
- MREO N/A
- Revenue
- LAES $10,981,000.00
- MREO N/A
- Revenue This Year
- LAES N/A
- MREO N/A
- Revenue Next Year
- LAES N/A
- MREO $38.38
- P/E Ratio
- LAES N/A
- MREO N/A
- Revenue Growth
- LAES N/A
- MREO N/A
- 52 Week Low
- LAES $0.29
- MREO $1.57
- 52 Week High
- LAES $11.00
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- LAES 38.22
- MREO 33.18
- Support Level
- LAES $2.92
- MREO $1.64
- Resistance Level
- LAES $3.08
- MREO $1.83
- Average True Range (ATR)
- LAES 0.20
- MREO 0.09
- MACD
- LAES -0.05
- MREO 0.01
- Stochastic Oscillator
- LAES 11.06
- MREO 8.04
About LAES SEALSQ Corp
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).